Optimising lipid monitoring interval for primary prevention of cardiovascular disease in patients with type-2 diabetes: A target trial emulation study
Lipid monitoring frequency in T2DM may be individualized by baseline LDL‑C level, with intervals of approximately 16-24, 9-15, and 2-8 months representing minimum frequencies.
Authors
- Celine Sze Ling Chui (ORCID: https://orcid.org/0000-0003-1513-8726)
- Cindy Lo Kuen Lam (ORCID: https://orcid.org/0000-0001-7536-8481)
- Emily Tsui Yee Tse
- Boyuan Wang
- Eric Yuk Fai Wan
Institutions
- University of Hong Kong - Shenzhen Hospital (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Diabetes Research and Clinical Practice
- Published
- 2026-02-13
- DOI
- https://doi.org/10.1016/j.diabres.2026.113156
- Primary Topic
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Pfizer
- National Natural Science Foundation of China
- Innovation and Technology Commission
- Hospital Authority
- Hong Kong Government
- Kerry Group Kuok Foundation
- Young Scientists Fund